What is Inhibikase Therapeutics, Inc.'s earnings per share (EPS)?

Inhibikase Therapeutics, Inc. (IKT) reported diluted earnings per share of -$0.49 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Inhibikase Therapeutics, Inc. (IKT) Financials

IKT

FY2025 annual

Net Income -$48.3M -75.4% YoY

EPS (Diluted) -$0.49 YoY not available

Free Cash Flow -$27.8M -45.2% YoY

Operating Cash Flow -$27.8M -45.1% YoY

Market Cap $279.1M as of Oct 3, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.8x on $153.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IKT SEC filings page.

This page shows Inhibikase Therapeutics, Inc. (IKT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IKT FY2025 2026-10-03

The company remains a development-stage operation: rising research spending and losses are funded mainly through external financing, not operating revenue.

From FY2023 to FY2025, R&D spending more than doubled from $13.6M to $29.8M, while operating cash flow remained negative; that pattern identifies a development program expanding before commercial cash generation. Operating cash flow shifted from -$18.1M to -$27.8M over the same span, linking the larger research budget to a greater funding need.

FY2025's net loss of $48.3M was materially larger than its operating cash outflow of $27.8M, while free cash flow was nearly identical to operating cash flow. That gap indicates accounting charges or timing effects that did not immediately consume cash; capital expenditures were only $13K, so cash needs center on ongoing research and administration rather than physical reinvestment.

The balance sheet is equity-heavy: FY2025 liabilities were $8.3M against $181.2M of assets, leaving little reliance on obligations to fund the asset base. Financing cash flow supplied $108.5M, and reported liquidity equaled 94.3 months of the latest annual operating outflow, so disclosed funding is dominated by external capital rather than internally generated cash.

Financial Health Signals

Financial health score not available

Inhibikase Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Inhibikase Therapeutics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Inhibikase Therapeutics, Inc. reported a net loss of $48.3M while operations used $27.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Inhibikase Therapeutics, Inc. reported an operating loss of $52.0M against $3.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Inhibikase Therapeutics, Inc. generated $0 in revenue in Q2 2026.

EBITDA

-$21.1M

YoY-94.8%

QoQ-18.0%

Inhibikase Therapeutics, Inc.'s EBITDA was -$21.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 94.8% from the same quarter a year earlier. Against the prior quarter it is down 18.0%.

Net Income

-$19.6M

YoY-97.6%

QoQ-19.6%

Inhibikase Therapeutics, Inc. reported -$19.6M in net income in Q2 2026. This represents a decrease of 97.6% from the same quarter a year earlier. Against the prior quarter it is down 19.6%.

EPS (Diluted)

-$0.11

QoQ-10.0%

Inhibikase Therapeutics, Inc. earned -$0.11 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 10.0%.

Cash & Balance Sheet

Free Cash Flow

-$12.4M

YoY-123.2%

QoQ-3.2%

Inhibikase Therapeutics, Inc. recorded an outflow of $12.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 123.2% from the same quarter a year earlier. Against the prior quarter it is down 3.2%.

Cash & Debt

$31.2M

YoY-59.9%

QoQ-37.0%

5Y CAGR-7.8%

Inhibikase Therapeutics, Inc. held $31.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

140M

QoQ+5.7%

5Y CAGR+40.9%

Inhibikase Therapeutics, Inc. had 140M shares outstanding in Q2 2026. Against the prior quarter it is up 5.7%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-12.8%

YoY-0.4pp

QoQ-3.0pp

Inhibikase Therapeutics, Inc.'s ROE was -12.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.0 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$13.4M

YoY+154.1%

QoQ+23.6%

Inhibikase Therapeutics, Inc. invested $13.4M in research and development in Q2 2026. This represents an increase of 154.1% from the same quarter a year earlier. Against the prior quarter it is up 23.6%.

Capital Expenditures

Inhibikase Therapeutics, Inc. reported no capital expenditure in Q2 2026.

Share Buybacks

Not reported for Q2 2026.

IKT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IKT quarterly income statement

Metric	TTM	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	N/A	N/A	$0-100.0%	$261K+111.0%	$123K-96.0%	$3.1M+343.9%	$698K
R&D Expenses	N/A	$29.8M+73.1%	$17.2M+26.4%	$13.6M+13.2%	$12.0M+6.0%	$11.4M+1170.9%	$894K
SG&A Expenses	N/A	$23.6M+107.0%	$11.4M+69.0%	$6.7M+8.3%	$6.2M-4.5%	$6.5M+148.1%	$2.6M
Operating Income	N/A	-$52.0M-81.8%	-$28.6M-42.3%	-$20.1M-10.8%	-$18.1M-22.8%	-$14.8M-423.9%	-$2.8M
EBITDA	N/A	-$51.9M-81.8%	-$28.6M-43.4%	-$19.9M-9.9%	-$18.1M-22.7%	-$14.8M	N/A
Interest Expense	N/A	$3.7M+247.5%	$1.1M+0.8%	$1.1M+1324.9%	$74K+273.7%	$20K-32.2%	$29K
Income Tax	N/A	$0	$0	N/A	N/A	N/A	N/A
Net Income	N/A	-$48.3M-75.4%	-$27.5M-44.6%	-$19.0M-5.4%	-$18.1M-22.1%	-$14.8M-419.2%	-$2.8M
EPS (Basic)	N/A	-$0.49+57.8%	-$1.16+63.3%	-$3.16+26.2%	-$4.28-428.4%	-$0.81	N/A
EPS (Diluted)	—	-$0.49	-$1.16	-$3.16	-$4.28	-$0.81	N/A
Diluted Shares (Avg)	N/A	98M	24M	6M	4M	18M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0-100.0%
R&D Expenses	$13.4M+154.1%	$10.8M+3.1%	N/A	$7.6M+82.6%	$5.3M+71.4%	$10.5M+282.1%	N/A	$4.2M+29.9%
SG&A Expenses	$7.7M+29.4%	$7.4M+40.5%	N/A	$5.6M+242.7%	$5.9M+199.8%	$5.2M+158.4%	N/A	$1.6M+0.9%
Operating Income	-$21.1M-94.3%	-$17.8M-22.2%	N/A	-$12.8M-119.1%	-$10.8M-114.5%	-$14.6M-205.2%	N/A	-$5.8M-22.2%
EBITDA	-$21.1M-94.8%	-$17.8M-22.3%	N/A	-$12.7M-118.9%	-$10.8M-114.3%	-$14.6M-205.4%	N/A	-$5.8M-22.2%
Interest Expense	$1.5M+59.2%	$1.5M+58.9%	N/A	$838K+1596.2%	$917K+908.2%	$919K+592.6%	N/A	$49K-71.6%
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$19.6M-97.6%	-$16.4M-19.8%	N/A	-$11.9M-106.5%	-$9.9M-99.9%	-$13.7M-194.2%	N/A	-$5.8M-25.7%
EPS (Basic)	-$0.110.0%	-$0.10+33.3%	-$0.09-110.3%	-$0.13+80.0%	-$0.11+83.3%	-$0.15+79.5%	$0.87+235.9%	-$0.65+24.4%
EPS (Diluted)	-$0.11	-$0.10	-$0.09-110.3%	-$0.13	-$0.11	-$0.15	$0.87	-$0.65
Diluted Shares (Avg)	175M	172M	N/A	90M	90M	90M	N/A	9M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

IKT Balance Sheet

IKT quarterly balance sheet

Metric	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$181.2M+83.8%	$98.6M+579.7%	$14.5M-41.8%	$24.9M-41.3%	$42.5M+187.3%	$14.8M
Current Assets	$180.1M+82.9%	$98.5M+592.8%	$14.2M-41.7%	$24.4M-42.6%	$42.5M+187.3%	$14.8M
Cash & Equivalents	$178.8M+83.4%	$97.5M+959.8%	$9.2M+28.0%	$7.2M-82.4%	$40.8M+192.0%	$14.0M
Short-Term Investments	$39.5M-3.7%	$41.1M+904.5%	$4.1M-74.2%	$15.9M	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0
Total Liabilities	$8.3M+122.3%	$3.7M+5.8%	$3.5M-9.5%	$3.9M-3.8%	$4.1M-18.9%	$5.0M
Current Liabilities	$8.3M+122.3%	$3.7M+8.6%	$3.4M-7.0%	$3.7M-8.9%	$4.1M-14.1%	$4.7M
Non-Current Liabilities	$0	$0-100.0%	$90K-56.1%	$205K	$0-100.0%	$276K
Long-Term Debt	N/A	N/A	$382K	N/A	$249K	N/A
Total Equity	$172.9M+82.3%	$94.9M+764.2%	$11.0M-47.8%	$21.0M-45.2%	$38.4M+292.6%	$9.8M
Retained Earnings	-$142.7M-51.1%	-$94.4M-41.1%	-$66.9M-39.7%	-$47.9M-60.5%	-$29.8M-298.4%	$15.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$163.6M+84.1%	$173.3M+83.8%	$181.2M+83.8%	$79.6M+1718.5%	$88.9M+906.6%	$94.3M+751.8%	$98.6M+579.7%	$4.4M-75.5%
Current Assets	$162.3M+82.8%	$172.2M+82.8%	$180.1M+82.9%	$78.5M+1774.3%	$88.8M+932.2%	$94.2M+771.3%	$98.5M+592.8%	$4.2M-76.1%
Cash & Equivalents	$31.2M-59.9%	$49.6M-32.5%	$178.8M+83.4%	$38.3M+4089.7%	$77.7M+2418.8%	$73.4M+3020.7%	$97.5M+959.8%	$913K-93.9%
Short-Term Investments	$127.8M+1188.0%	$120.8M+512.0%	$39.5M-3.7%	$39.1M+1575.9%	$9.9M+104.4%	$19.7M+166.9%	$41.1M+904.5%	$2.3M+18.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$10.3M+16.6%	$5.7M-33.2%	$8.3M+122.3%	$6.7M+36.5%	$8.8M+135.9%	$8.6M+99.2%	$3.7M+5.8%	$4.9M+71.4%
Current Liabilities	$10.3M+16.6%	$5.7M-33.2%	$8.3M+122.3%	$6.7M+36.5%	$8.8M+137.5%	$8.6M+102.0%	$3.7M+8.6%	$4.9M+79.0%
Non-Current Liabilities	$0	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%
Total Equity	$153.3M+91.5%	$167.6M+95.5%	$172.9M+82.3%	$72.9M+13839.1%	$80.1M+1470.7%	$85.7M+1165.1%	$94.9M+764.2%	-$531K-103.5%
Retained Earnings	-$178.7M-51.4%	-$159.1M-47.1%	-$142.7M-51.1%	-$129.9M-57.9%	-$118.0M-54.2%	-$108.1M-51.1%	-$94.4M-41.1%	-$82.3M-31.2%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

IKT Cash Flow Statement

IKT quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$42.6M	-$27.8M-45.1%	-$19.1M-5.9%	-$18.1M-4.2%	-$17.4M-21.4%	-$14.3M-1165.9%	-$1.1M
Depreciation & Amortization	N/A	$60K+130.3%	$26K-85.2%	$177K+2538.7%	$7K	$0	N/A
Stock-Based Compensation	N/A	$15.3M+88.1%	$8.1M+1527.6%	$500K+9.2%	$458K-70.1%	$1.5M+167.0%	$574K
Capital Expenditures	$0	$13K	$0-100.0%	$14K-94.1%	$243K	$0	N/A
Free Cash Flow	-$42.6M	-$27.8M-45.2%	-$19.1M-5.8%	-$18.1M-2.9%	-$17.6M-23.1%	-$14.3M	N/A
Investing Cash Flow	-$115.2M	$2.1M+105.5%	-$37.0M-417.5%	$11.7M+172.8%	-$16.0M	$0	N/A
Financing Cash Flow	$111.3M	$108.5M+4.8%	$103.5M+1131.1%	$8.4M+4204.6%	-$205K-100.5%	$41.1M+172.8%	$15.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$12.4M-123.2%	-$12.1M-193.9%	-$7.5M-40.6%	-$10.6M-117.0%	-$5.6M-10.3%	-$4.1M-6.1%	-$5.3M-55.3%	-$4.9M-18.9%
Depreciation & Amortization	$0-100.0%	$0-100.0%	$0-100.0%	$24K+260.7%	$24K+267.7%	$13K+92.7%	$7K0.0%	$7K0.0%
Stock-Based Compensation	$5.3M+27.0%	$5.6M+172.2%	N/A	$4.5M+2957.1%	$4.2M+13610.6%	$2.0M+3721.9%	N/A	$148K+14.1%
Capital Expenditures	$0	$0-100.0%	$0	$0	$0	$13K	$0	$0
Free Cash Flow	-$12.4M-123.2%	-$12.1M-192.9%	-$7.5M-40.6%	-$10.6M-117.0%	-$5.6M-10.3%	-$4.1M-6.5%	-$5.3M-55.3%	-$4.9M-18.9%
Investing Cash Flow	-$5.9M-160.0%	-$80.5M-482.3%	-$99K+99.7%	-$28.7M-1238.0%	$9.8M+287.1%	$21.1M+735.7%	-$38.8M-1732.2%	$2.5M-85.2%
Financing Cash Flow	-$14K-145.6%	$2.9M	$108.6M+8.9%	-$134K-173.7%	$32K-99.0%	$0-100.0%	$99.7M+72280.7%	$182K+259834.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

IKT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IKT quarterly financial ratios

Metric	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Margin	N/A	N/A	-7712.0%	-14686.2%	-476.2%	-403.5%
Net Margin	N/A	N/A	-7304.7%	-14625.9%	-476.9%	-407.7%
Return on Equity	-27.9%+1.1pp	-29.0%+144.3pp	-173.3%-87.5pp	-85.8%-47.3pp	-38.5%-9.4pp	-29.1%
Return on Assets	-26.6%+1.3pp	-27.9%+103.3pp	-131.2%-58.8pp	-72.4%-37.6pp	-34.8%-15.6pp	-19.3%
Current Ratio	21.70-4.7x	26.37+22.2x	4.13-2.5x	6.59-3.9x	10.47+7.3x	3.13
Debt-to-Equity	0.050.0x	0.040.0x	0.03-0.2x	0.19+0.2x	0.01-0.5x	0.51
Asset Turnover	N/A	0.000.0x	0.020.0x	0.01-0.1x	0.070.0x	0.05
FCF Margin	N/A	N/A	-6947.9%	-14253.4%	-461.1%	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-12.8%-0.4pp	-9.8%+6.2pp	N/A	-16.4%	-12.4%+84.9pp	-16.0%+52.7pp	N/A	N/A
Return on Assets	-12.0%-0.8pp	-9.4%+5.1pp	N/A	-15.0%+117.0pp	-11.2%+45.0pp	-14.5%+27.5pp	N/A	-132.0%-106.3pp
Current Ratio	15.82+5.7x	30.14+19.1x	21.70-4.7x	11.73+10.9x	10.09+7.8x	11.01+8.5x	26.37+22.2x	0.85-5.5x
Debt-to-Equity	0.070.0x	0.03-0.1x	0.050.0x	0.09	0.11-0.6x	0.10-0.5x	0.040.0x	N/A
Asset Turnover	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Inhibikase Therapeutics, Inc. IKT	FY2025	N/A	-$48.3M	N/A	$279.1M	—
Zura Bio Limited ZURA	FY2025	N/A	-$68.7M	N/A	$393.9M	—
Forte Biosciences, Inc. FBRX	FY2025	N/A	-$69.4M	N/A	$1.6B	—
IO Biotech, Inc. IOBT	FY2025	N/A	-$95.5M	N/A	$3.5M	—
Protara Therapeutics, Inc. TARA	FY2025	N/A	-$57.4M	N/A	$159.6M	—
KALA BIO, Inc. KALA	FY2025	$0	-$27.0M	N/A	$7.4M	—

Where Inhibikase Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Inhibikase Therapeutics, Inc. profitable?

No, Inhibikase Therapeutics, Inc. (IKT) reported a net income of -$48.3M in fiscal year 2025.

What is Inhibikase Therapeutics, Inc.'s EBITDA?

Inhibikase Therapeutics, Inc. (IKT) had EBITDA of -$51.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Inhibikase Therapeutics, Inc.'s return on equity (ROE)?

Inhibikase Therapeutics, Inc. (IKT) has a return on equity of -27.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Inhibikase Therapeutics, Inc.'s free cash flow?

Inhibikase Therapeutics, Inc. (IKT) recorded an outflow of $27.8M in free cash flow during fiscal year 2025. This represents a -45.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Inhibikase Therapeutics, Inc.'s operating cash flow?

Inhibikase Therapeutics, Inc. (IKT) recorded an outflow of $27.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Inhibikase Therapeutics, Inc.'s total assets?

Inhibikase Therapeutics, Inc. (IKT) had $181.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Inhibikase Therapeutics, Inc.'s capital expenditures?

Inhibikase Therapeutics, Inc. (IKT) invested $13K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Inhibikase Therapeutics, Inc. spend on research and development?

Inhibikase Therapeutics, Inc. (IKT) invested $29.8M in research and development during fiscal year 2025.

How many shares does Inhibikase Therapeutics, Inc. have outstanding?

Inhibikase Therapeutics, Inc. (IKT) had 132M shares outstanding as of fiscal year 2025.

What is Inhibikase Therapeutics, Inc.'s current ratio?

Inhibikase Therapeutics, Inc. (IKT) had a current ratio of 21.70 as of fiscal year 2025, which is generally considered healthy.

What is Inhibikase Therapeutics, Inc.'s debt-to-equity ratio?

Inhibikase Therapeutics, Inc. (IKT) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Inhibikase Therapeutics, Inc.'s return on assets (ROA)?

Inhibikase Therapeutics, Inc. (IKT) had a return on assets of -26.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Inhibikase Therapeutics, Inc.'s P/E ratio?

Inhibikase Therapeutics, Inc. (IKT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $279.1M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Inhibikase Therapeutics, Inc.'s price-to-sales ratio?

Inhibikase Therapeutics, Inc. (IKT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $279.1M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Inhibikase Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Inhibikase Therapeutics, Inc. (IKT) held $218.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.8M over that year. Dividing the one by the other, the reported balance equals about 94 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Inhibikase Therapeutics, Inc.'s Piotroski F-Score?

Inhibikase Therapeutics, Inc. (IKT) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Inhibikase Therapeutics, Inc.'s earnings high quality?

Inhibikase Therapeutics, Inc. (IKT) reported a net loss of $48.3M while operations used $27.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Inhibikase Therapeutics, Inc. cover its interest payments?

Inhibikase Therapeutics, Inc. (IKT) reported an operating loss of $52.0M against $3.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.